Such results suggest on one hand that BH3 mimetics may not totally substitute for the lack of an active p53 tumor suppressor in cancer cells; on the other hand, they imply that healthy tissues may be more harmed than anticipated when BCL-xL inhibitors are combined with chemotherapeutic agents that even mildly affect p53. The gene discussed is BCL2L1; the disease is cancer.